Exploiting Mitochondrial Dysfunction in Imatinib-Resistant Leukemic Cells
Author Information
Author(s): Kluza Jérome, Jendoubi Manel, Ballot Caroline, Dammak Abir, Jonneaux Aurélie, Idziorek Thierry, Joha Sami, Dauphin Véronique, Malet-Martino Myriam, Balayssac Stéphane, Maboudou Patrice, Briand Gilbert, Formstecher Pierre, Quesnel Bruno, Marchetti Philippe
Primary Institution: Université de Lille II, Lille, France
Hypothesis
Imatinib-resistant leukemic cells exhibit altered glucose metabolism and mitochondrial dysfunction that can be therapeutically exploited.
Conclusion
Imatinib-resistant leukemic cells have mitochondrial dysfunction that can be targeted for selective treatment using pro-oxidants.
Supporting Evidence
- Imatinib-resistant cells showed increased glycolysis compared to sensitive cells.
- Mitochondria in resistant cells had altered function and produced more reactive oxygen species (ROS).
- Treatment with pro-oxidants led to increased cell death in imatinib-resistant cells.
- Knockdown of HIF-1α reduced glycolytic activity in resistant cells.
- Imatinib-resistant cells had a higher NADH/NAD+ ratio indicating mitochondrial dysfunction.
- Accumulation of TCA cycle intermediates was observed in resistant cells.
- Pro-oxidants selectively killed imatinib-resistant cells through ROS-mediated mechanisms.
- Animal models showed prolonged survival with pro-oxidant treatment in imatinib-resistant leukemia.
Takeaway
Some leukemia cells that don't respond to a common drug have sick mitochondria, and we can use this to help kill them with special treatments.
Methodology
The study involved cell culture experiments, metabolic profiling, and in vivo mouse models to assess mitochondrial function and response to treatments.
Potential Biases
Potential bias in the selection of cell lines and patient samples may affect the generalizability of the findings.
Limitations
The study primarily focused on specific cell lines and may not fully represent all imatinib-resistant leukemia cases.
Participant Demographics
Bone marrow samples were obtained from 4 CML patients resistant to imatinib.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website